Targeting the spatial-metabolic-immune ecosystem in colorectal Cancer liver metastasis: pharmacological strategies...

Colorectal cancer liver metastasis (CRLM) remains the primary driver of mortality in advanced disease, largely due to a highly suppressive hepatic ecosystem that limits the efficacy of immune checkpoint inhibitors (ICIs). Current evidence suggests that therapeutic resistance arises from the integrated co-evolution of tissue architecture, metabolic reconfiguration, and immune remodeling. Here, we define a distinct "Spatial-Metabolic-Immune Coupling Network" as a critical barrier and a potential pharmacological target. We dissect how microanatomical domains, including the hypoxic tumor core and fibrotic stromal barrier, synergistically orchestrate multidrug resistance. Importantly, current pharmacotherapy often fails due to the neglected spatiotemporal heterogeneity of these mechanisms. To address this, we propose a dynamic "Break-Normalize-Reset" therapeutic paradigm. Unlike static combinations, this sequential strategy aims to pharmacologically (1) dismantle physical barriers, (2) reverse metabolic checkpoints, and (3) unleash antitumor immunity. Ultimately, this review advocates a paradigm shift from local lesion management to the systemic ecological reconstruction, providing a pharmacological framework for next-generation combination therapies in CRLM.